Generic Medicine Info
Indications and Dosage
Type 2 diabetes mellitus
Adult: 12.5-75 mg daily. Doses ≥50 mg daily are given in 2 divided doses.
Type 1 diabetes mellitus; ketoacidosis; severe infection; trauma; other severe conditions where glibornuride is unlikely to control the hyperglycaemia; renal or hepatic impairment; porphyria; pregnancy; lactation.
Special Precautions
Elderly, debilitated or malnourished patients; adrenal or pituitary insufficiency. Monitor blood glucose concentration.
Adverse Reactions
GI disturbances; metallic taste; skin rashes, pruritus, photosensitivity; facial flushing; hypoglycaemia; syndrome of inappropriate secretion of antidiuretic hormone; cholestatic jaundice; Stevens-Johnson syndrome; exfoliative dermatitis; erythema nodosum; increased appetite; wt gain; blood disorders.
Drug Interactions
Diminished hypoglycaemic effect with adrenaline, aminoglutethimide, chlorpromazine, corticosteroids, diazoxide, oral contraceptives, rifamycins and thiazide diuretics. Increased hypoglycaemic effect with ACE inhibitors, alcohol, allopurinol, some analgesics, azole antifungals, chloramphenicol, cimetidine, clofibrate and related compounds, coumarin anticoagulants, halofenate, heparin, MAOIs, octreotide, ranitidine, sulfinpyrazone, sulfonamides, tetracyclines, tricyclic antidepressants and thyroid hormones. β-blockers increase hypoglycaemia and mask typical sympathetic warning signs.
Lab Interference
Altered liver enzyme values.
Mechanism of Action: Glibornuride acts by stimulating insulin secretion and is effective only when some residual pancreatic β-cell activity is present.
MIMS Class
Antidiabetic Agents
Disclaimer: This information is independently developed by MIMS based on Glibornuride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in